Su et al. [19] found regorafenib reduced protein expression of VEGF through suppression of signal transducer and activator of transcription 3 (STAT-3) activation in triple negative breast cancer cells in vitro and in vivo. The gene discussed is STAT3; the disease is triple-negative breast carcinoma.